BR0308415A - Métodos de tratamento de diabetes usando-se inibidores de pde11a - Google Patents
Métodos de tratamento de diabetes usando-se inibidores de pde11aInfo
- Publication number
- BR0308415A BR0308415A BR0308415-9A BR0308415A BR0308415A BR 0308415 A BR0308415 A BR 0308415A BR 0308415 A BR0308415 A BR 0308415A BR 0308415 A BR0308415 A BR 0308415A
- Authority
- BR
- Brazil
- Prior art keywords
- pde11a
- inhibitors
- methods
- insulin
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36469702P | 2002-03-14 | 2002-03-14 | |
| US38903602P | 2002-06-13 | 2002-06-13 | |
| PCT/US2003/008132 WO2003077949A2 (en) | 2002-03-14 | 2003-03-14 | Methods of treating diabetes using pde 11a inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308415A true BR0308415A (pt) | 2005-02-15 |
Family
ID=28045431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308415-9A BR0308415A (pt) | 2002-03-14 | 2003-03-14 | Métodos de tratamento de diabetes usando-se inibidores de pde11a |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1496940A2 (es) |
| JP (1) | JP2005527524A (es) |
| AU (1) | AU2003220342B2 (es) |
| BR (1) | BR0308415A (es) |
| CA (1) | CA2477832A1 (es) |
| MX (1) | MXPA04008195A (es) |
| WO (1) | WO2003077949A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008502909A (ja) * | 2004-06-15 | 2008-01-31 | メタボレックス インコーポレーティッド | 糖尿病およびインスリン抵抗性の診断および治療の方法 |
| BRPI0716134A2 (pt) | 2006-09-07 | 2013-09-17 | Nycomed Gmbh | tratamento de combinaÇço para diabetes mellitus |
| WO2008149345A2 (en) | 2007-06-04 | 2008-12-11 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
| WO2009108383A2 (en) | 2008-02-29 | 2009-09-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| EP2408443A1 (en) * | 2009-03-16 | 2012-01-25 | Genmedica Therapeutics SL | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| US20140296263A1 (en) | 2011-07-19 | 2014-10-02 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| JP2015067538A (ja) * | 2013-09-26 | 2015-04-13 | 株式会社アイエイアイ | 血糖値降下剤 |
| CN106061940A (zh) | 2013-11-05 | 2016-10-26 | 本古里安大学内盖夫研究发展局 | 治疗糖尿病和由其引发的并发疾病的化合物 |
| EP3131554A1 (en) | 2014-04-18 | 2017-02-22 | Concert Pharmaceuticals Inc. | Methods of treating hyperglycemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| AU2001285782A1 (en) * | 2000-06-26 | 2002-01-08 | Bayer Aktiengesellschaft | Regulation of human phosphodiesterase-like enzyme |
| EP1211313A3 (en) * | 2000-11-01 | 2003-04-23 | Pfizer Limited | Modulation of PDE11A activity |
-
2003
- 2003-03-14 WO PCT/US2003/008132 patent/WO2003077949A2/en not_active Ceased
- 2003-03-14 JP JP2003576002A patent/JP2005527524A/ja not_active Withdrawn
- 2003-03-14 MX MXPA04008195A patent/MXPA04008195A/es not_active Application Discontinuation
- 2003-03-14 AU AU2003220342A patent/AU2003220342B2/en not_active Expired - Fee Related
- 2003-03-14 BR BR0308415-9A patent/BR0308415A/pt not_active IP Right Cessation
- 2003-03-14 CA CA002477832A patent/CA2477832A1/en not_active Abandoned
- 2003-03-14 EP EP03716641A patent/EP1496940A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003220342B2 (en) | 2007-06-07 |
| WO2003077949A3 (en) | 2004-03-25 |
| JP2005527524A (ja) | 2005-09-15 |
| CA2477832A1 (en) | 2003-09-25 |
| MXPA04008195A (es) | 2004-11-26 |
| WO2003077949A2 (en) | 2003-09-25 |
| EP1496940A2 (en) | 2005-01-19 |
| AU2003220342A1 (en) | 2003-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Szentesi et al. | Changes in redox signaling in the skeletal muscle with aging | |
| Mense | Nociception from skeletal muscle in relation to clinical muscle pain | |
| JP4663984B2 (ja) | 疼痛の治療または防止に有用なチアジアゾリルピペラジン誘導体 | |
| Werner et al. | Erectile dysfunction in mice lacking the large‐conductance calcium‐activated potassium (BK) channel | |
| BR0011823A (pt) | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo | |
| EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
| BRPI0516825A (pt) | inibição da protease ns3-ns4a do vìrus da hepatite c (vhc) | |
| BRPI0509139A (pt) | composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor | |
| BRPI0618918B8 (pt) | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea | |
| BRPI0408784A (pt) | método para usar um composto | |
| BRPI0509573A (pt) | derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 | |
| BRPI0512535A (pt) | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações | |
| JP2005521679A (ja) | 疼痛の治療に有用な治療薬 | |
| DE602004030353D1 (de) | Formulierungen enthaltend salicylate und deren verwendung zur behandlung von entzündlicher darmerkrankung | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
| BR9917005A (pt) | Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete | |
| ATE480256T1 (de) | Plazentäre alkalische phosphatase zur diabeteskontrolle | |
| CA2958696C (en) | Formulations of testosterone and methods of treatment therewith | |
| BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
| BR0308415A (pt) | Métodos de tratamento de diabetes usando-se inibidores de pde11a | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| Shuttleworth et al. | Regulation of citrulline recycling in nitric oxide‐dependent neurotransmission in the murine proximal colon | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| EP1742643A4 (en) | MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 3A, 4A, 5A, 6A E 7A ANUIDADE(S). |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |